We are developing new gene therapy vectors whose expression is selectively activated by hypoxia, a unique feature of human solid tumors. As vascular endothelial growth factor (VEGF) is upregulated by hypoxia, such regulatory mechanisms would enable us to achieve hypoxia-inducible expression of therapeutic genes. Constructs with five copies of hypoxia-responsive elements (HREs) derived from the 5 ′-untranslated region (UTR) of the human VEGF showed excellent transcriptional activation at low oxygen tension relevant to tumor hypoxia. In an attempt to achieve higher responsiveness, various combinations of HREs and promoters were examined. In addition, we also investigated
Introduction
A fundamental problem for cancer gene therapy is the lack of a tumor-selective delivery system. One approach to overcome this, at least in part, is to develop tumor specific gene expression. At present, preclinical studies are underway to investigate the utility of tumor-or tissue-specific promoters such as prostate-specific antigen promoters for prostate cancers, 1 carcinoembryonic antigen promoters for colorectal cancers, 2 and erbB2 promoters for breast cancers. 3 Recent studies have also explored the potential of exploiting tumor hypoxia as a gene therapy target. [4] [5] [6] [7] Hypoxia, a unique feature of human solid tumors, 8 has been considered to be a major factor in the resistance of cancers to radiotherapy and chemotherapy. Recent clinical studies using oxygen electrodes have provided compelling evidence that human tumors contain regions at low oxygen partial pressure, and that the more hypoxic tumors have a poor prognosis after treatment. [9] [10] [11] Besides these effects on treatment outcome, hypoxia is a potent signal inducing the expression of a number of genes including erythropoietin (Epo), VEGF, and various glycolytic enzymes. [12] [13] [14] Hypoxia responsible elements (HREs) have been reported in the 3′ flanking region of the human and mouse Epo genes, and a hypoxia-inducible factor 1 (HIF-1) has been shown to bind to the consensus whether the 3 ′ UTR of the VEGF gene would confer increased post-transcriptional mRNA stability under hypoxic conditions.
However, despite increases in the hypoxic/aerobic ratio of luciferase activity, gene expression with 3′ UTR was lower due to mRNA destabilization by AUrich elements (AREs). Thus, we found no benefit from the inclusion of the 3 ′ UTR in our vectors. Of all the vectors tested, the combination of 5HRE and a CMV minimal promoter exhibited hypoxia responsiveness (over 500-fold) to the similar level to the intact CMV promoter. We propose that this vector would be useful for tumor selective gene therapy. Gene Therapy (2000) 7, 493-498.
sequence in the Epo HRE. 15, 16 Similar HIF-1 binding sequences have been found in the 5′ flanking region of other hypoxia inducible genes including VEGF. [17] [18] [19] Such regulatory mechanisms for hypoxia responsive gene expression could provide a means for tumor-specific therapeutic approaches. Dachs et al 6 have demonstrated that heterologous gene expression driven by HREs from the mouse phosphoglycerate kinase-1 (PGK-1) gene could be activated in hypoxic tumor cells. We have previously shown that a vector with five copies of HRE and a E1b minimal promoter exhibited a 40-to 50-fold increase in gene expression under hypoxia when transiently transfected into human tumor cells. 7 However, despite its robust responsiveness under hypoxia, the amount of luciferase activity for this vector was considerably smaller than that produced by a CMV promoter vector, and may be insufficient to achieve gene expression for genetically directed enzyme prodrug therapy (GDEPT). We have therefore carried out further studies with the goal of establishing hypoxia-inducible vectors with higher expression of therapeutic genes.
In addition to transcriptional activation via HIF-1 binding to HREs, post-transcriptional regulation of the VEGF mRNA stability may be an important factor for up-regulation of VEGF expression under hypoxia. Recent studies in an in vitro RNA degradation assay revealed that some genetic elements for mRNA stability are located in the 3′ UTR. [20] [21] [22] The VEGF 3′ UTR contains a cluster of AU-rich elements (ARE) including the AUUUA pentamer and the UUAUUUAUU nonamer, as do many labile mRNAs encoding lymphokines, cytokines, transcriptional factors, and proto-oncogenes. [23] [24] [25] Five hypoxia-inducible RNA protein-binding sites have been identified in human and rat genes that might regulate mRNA stability under hypoxia. 22, 26 However, the usefulness of such post-transcriptional mechanisms in hypoxia-inducible vectors is not clear. Levy et al 26 reported that transfer of the rat VEGF 3′ UTR to a heterologous gene does not confer hypoxia-inducible mRNA stability on the heterologous transcript. However, Damert et al 27 have published that a reporter vector with the 3′ UTR of the mouse VEGF gene produced a marked increase in ␤-galactosidase activity within experimental gliomas, suggesting that an increase in mRNA stability may contribute to VEGF induction under hypoxic conditions. Such different regulatory mechanisms may provide the potential of exploiting tumor hypoxia for targeted gene expression.
To characterize further the transcriptional activation capacity of HREs from human VEGF under hypoxic conditions, we examined the aerobic and hypoxic responsiveness of luciferase reporter genes as a function of oxygen concentration. We also examined whether post-transcriptional mRNA stabilization by VEGF 3′ UTR could improve hypoxia inducibility. In order to increase the hypoxia inducible level of gene expression, we tested various constructs to determine the most optimal combination of HREs and several promoter elements. We found that a construct composed of 5HRE ligated to a human CMV minimal promoter increased gene expression over 500-fold in response to hypoxia, reaching levels comparable to that obtained by the full length CMV IE promoter. This vector, therefore, may be useful in an appropriate vehicle to obtain tumor-specific gene expression by exploiting tumor hypoxia.
Results
Oxygen dependent inducibility of a hypoxia-inducible vector with 5HRE In our previous study, a 5HRE/VEGF/E1b vector showed a significant increase in luciferase expression in transient transfected human tumors after 6 h of hypoxic exposure. Because human tumors contain cells at various oxygen concentrations, we measured transcriptional induction of our 5HRE reporter gene as a function of oxygen concentration. HT1080 cells were transfected with 5 g of vector DNA per 5 × 10 5 cells, exposed to various oxygen concentrations between 21% and 0.02% for 6 h, and assayed for luciferase activity. As shown in the Figure 1 , a significant increase in luciferase activity was detected below 2% oxygen and continued to increase as oxygen levels decreased, as reported earlier. 28 For the 5HRE/VEGF/E1b vector, a 40-to 50-fold increase was observed after 6 h hypoxic treatment at 0.02% O 2 . These data suggested that hypoxia mediated transcriptional activation could be achieved under oxygen levels relevant to those in human solid tumors.
Effects of copy number of HREs on hypoxia inducible gene expression
We next examined the effect of increasing HRE copy number of HREs on the hypoxia inducibility of the luciferase reporter gene. A series of the reporter vectors with three to 10 copies of HRE ligated to the SV40 promoter derived from the pGL3 vector or the E1b minimal promoter were generated as depicted in the Figure 2 . For all the pGL3 vector constructs with HREs, significant increases in luciferase activity were observed after 6 h of hypoxic treatment at 0.02% O 2 . The hypoxic/aerobic ratios ranged about 20-60-fold and increased with the numbers of HREs. However, a saturation effect was observed for vectors with more than five copies of HREs.
We also compared the hypoxia responsiveness of constructs with five and 10 copies of HREs in a series of reporter genes with an E1b minimal promoter. The hypoxic/aerobic ratios for both vectors were about 40 and 60 at 0.2 and 0.02% O 2 , respectively. Thus, five copies of HREs ligated to either basal promoter results in maximal hypoxia inducible expression.
The effect of the VEGF 3′ UTR on reporter gene inducibility Recent studies have suggested that VEGF mRNA could be stabilized post-transcriptionally under hypoxia through its 3′ UTR sequences. 20, 22, 26 Thus, the VEGF 3′ UTR could potentially enhance hypoxia responsiveness of HRE regulated gene constructs by increasing mRNA stability. To obtain 3′ UTR sequences, HT1080 cells were treated under hypoxia for 24 h, total RNAs was isolated, and RT-PCR was performed as described in Materials and methods. As 1.5 kb of the 3′ UTR fragment from this study encompasses all five hypoxia-inducible RNA protein binding sites reported by Levy et al 26 we ligated this fragment to the pGL3 and 5HRE/VEGF/E1b vectors as shown in Figure 3 .
HT1080 cells were transfected with the pGL3 and 5HRE/VEGF/E1b vectors with or without 1.5 kb of the 3′ UTR, allowed to recover for 36 h after transfection, exposed to 0.02% O 2 for 6-18 h, and assayed for luciferase activity. Significant increases in luciferase activity were detected after hypoxic treatment for the pGL3-3′ UTR vector in comparison with its aerobic control, while significant decreases were observed after 18 h hypoxia for the pGL3 vector. Although the addition of the 3′ UTR resulted in moderate increases (1.5-fold) in the hypoxic/aerobic ratios, the actual amount of luciferase activity for the pGL3-3′ UTR were smaller than that for the pGL3 vector.
Similarly, the hypoxic/aerobic ratios of approximately 200-fold that were obtained with the 3′ UTR for the 5HRE/VEGF/E1b series were mainly due to reduced luciferase activity under aerobic conditions. In fact, the actual amount of expression of reporter genes with 3′ UTR was smaller than reporter genes without the 3′ UTR under hypoxia. Thus, the 3′ UTR of the human VEGF gene produced both a marked destabilization under aerobic conditions and increased stability under hypoxia. Use of the CMV minimal promoter combined with HREs Although the 5HRE exhibited robust responsiveness under hypoxia, the actual amount of luciferase activity for the 5HRE/VEGF/E1b vector was about 100-fold lower than that for a CMV IE promoter-driven vector. As a reporter gene, the 5HRE/VEGF/E1b vector possessed low background activity in air and high responsiveness under hypoxia. However, even with maximum induction by hypoxia, it is unclear whether this would be effective in GDEPT because anti-tumor effects will likely depend critically on the actual amount of the prodrug activating enzyme. We therefore examined other constructs with the goal of achieving higher absolute expression levels under hypoxia. Two such constructs were derived from the human EF-1 alpha promoter, one of the strongest mammalian promoters, and a 60 bp minimal promoter containing a TATA sequence derived from the human CMV IE promoter.
As shown in Figure 4 , there was undetectable hypoxic induction with the 5HRE/EF-1 alpha vector. In fact, after 18 h hypoxic treatment at 0.02% O 2 , luciferase activity was markedly reduced. However, with the 5HRE/hCMVmp vector, we could detect more than a 500-fold induction by 18 h hypoxia at 0.02% O 2 . Both absolute levels of gene expression were high (about 0.4 of CMV I/E), and basal activity was slightly above background empty vector levels (less than 0.001 of CMV I/E). Also shown (Figure 4c ) is the oxygen dependence for induction by this vector. The data show a similar oxygen dependence for inducibility as the 5HRE/VEGF/E1b construct but with a larger dynamic range. Thus, among Figure 1. all the constructs tested, the 5HRE/hCMVmp appears to be the most promising vector that could be utilized in hypoxia-inducible gene therapy.
Figure 4 Comparison of 5HRE with different promoter elements. (a) Diagram of various combination of the HREs and promoters. (b) Comparison of the hypoxia inducibility for each vector. The luciferase activities are shown as relative values (mean and s.d.) to that for CMV IE vector under aerobic conditions. Hypoxic/aerobic ratios are also indicated. (c) The luciferase activity of the 5HRE/hCMVmp vector as a function of oxygen concentration. The procedures were the same as described in

Discussion
We and others have proposed that the lower level of oxygenation found in solid tumors compared with normal tissues may represent a means to target gene expression selectively to tumors. [6] [7] [8] 29 However, to date, there have been no reports of successful implementation of this strategy. Possible reasons include the need for levels of hypoxia/anoxia that are lower than those occurring in tumors, and/or inadequate specificity or potency of the vectors and therapeutic genes used. We have addressed these specific questions in the present studies.
Our results on the oxygen dependency of gene induction (Figure 1 ) suggest that the 5HRE-derived constructs give maximum gene expression in the human tumor cells at an oxygen concentration of 0.2% (1.5 mmHg) and halfmaximum activity at 1% oxygen concentration (5-7 mmHg). This finding is similar to that reported earlier for HIF-1 DNA-binding activity in HeLa cells, where a maximum response was obtained at 0.5% oxygen and a half-maximum at about 1.5% oxygen. 28 In several clinical series the average median pO 2 for carcinomas of the breast, head and neck, and cervix are 10-15 mmHg, with most tumors having areas with pO 2 values Ͻ5 mmHg.
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Further, we have recently shown that transplanted tumors in mice have even lower levels of oxygenation with average median values of 1-3 mmHg. 30 Thus, the activation of hypoxia-responsive genes acting through HIF-1 binding to HREs is in the ideal range for selective gene expression in human and experimental tumors.
The second question as to selectivity and potency deals with both relative and absolute expression under hypoxia. An earlier study of Dachs et al 6 using mouse PGK, TK, and 9-27 promoters with HREs driving a cytosine deaminase gene in stably transfected cells reported a 5.4-fold sensitization to 5-FC after 16 h hypoxia. Using a luciferase reporter assay following transient transfection we reported 40-to 50-fold increases in hypoxia induction with a construct containing five copies of a 35-bp fragment derived from the VEGF HRE and a 32-bp fragment of the E1b minimal promoter sequence. 7 However, maximum expression by this construct was some 100-fold lower than that achieved with a strong, constitutive promoter such as the cytomegalovirus (CMV) immediate/early promoter. In the present investigation we sought to increase both the specificity (relative hypoxia/aerobic expression) as well as the potency (absolute expression under hypoxia) of the hypoxiaresponsive vector.
Our first attempt was to use the fact that increased post-transcriptional stability of mRNA plays an important role in increased VEGF expression under hypoxic conditions. Several authors have reported that the half-life of VEGF mRNA is increased 2.5-to eightfold in response to hypoxia. [20] [21] [22] Damert et al 27 reported that stably transfected cells with LacZ reporter genes that possessed 3′ UTR sequences of the mouse VEGF gene showed positive staining for beta-galactosidase in the perinecrotic areas in transplanted tumors, suggesting that these sequences provide increased stability under hypoxia. Also a recent study by Claffey et al 31 showed that chimeric reporters containing VEGF 3′ UTR sequences between the luciferase coding sequence and the polyadenylation site were significantly increased by 12 h hypoxic incubation. Levy et al 26 identified five potential hypoxia-inducible protein binding sites by RNA electromobility shift assay in the human and rat 3′ UTR, providing a regulatory mechanism for mRNA stability. However, contrary to previous reports, we found that under hypoxia the luciferase expression with 3′ UTR was lower than that without these sequences under hypoxia even though the hypoxic/aerobic ratio was significantly increased with the 3′ UTR sequences. The reason for this is suggested by the fact that the VEGF 3′ UTR contains a cluster of AU repeats similar to that in many labile and rapid turnover mRNAs including those of cytokines, transcription factors and proto-oncogenes. Insertion of AREs from the 3′ UTR of granulocyte-macrophage colony-stimulating factor or c-fos has been also shown to destabilize a normally stable globin mRNA. 25, 32 Thus, we believe that the addition of the 3′ UTR from VEGF acted to destabilize the message under aerobic conditions, and this was partially reversed under hypoxia by putative hypoxia-induced RNA binding proteins. The result of this is that there was no advantage to adding the 3′ UTR to the reporter construct.
As noted above, the amount of gene expression with 5HRE/VEGF/E1b had an excellent hypoxia/aerobic ratio of approximately 100. However, the absolute levels of expression even with prolonged hypoxia were still approximately 100-fold lower than with a CMV-driven vector. Therefore, we tested the highly potent human EF-1 alpha promoter with 5HRE, but although this plasmid construct produced high levels of aerobic expression, there was no hypoxia inducibility ( Figure 4 ). When we replaced the E1b minimal promoter with a minimal sequence of the CMV IE promoter, we found an increased expression of over 500-fold by an 18 h hypoxia treatment. Importantly, this 5HRE/hCMVmp construct produced a level of expression that was almost equivalent to that produced by the full-length CMV IE promoter ( Figure 4 ). Similar minimal promoters derived from the CMV promoter have been used with multimers of tetracyclineresponsive operators originally reported by Gossen et al 33 and more than a 1000-fold induction of reporter gene expression has been achieved by addition of doxycycline for 24 h. 34 CMV minimal promoters were also activated to a significantly higher degree than a thymidine kinase minimal promoter. Thus, the choice of minimal promoters seems to be important, and the use of a CMV minimal promoter may be the best for transcriptional targeting strategies.
The present study provides a significant advance in hypoxia-selective gene expression than presently available. We believe that such constructs can be used to drive therapeutic genes such as enzymes that can metabolize nontoxic prodrugs into toxic drugs. The selective expression of these enzymes in the tumors will, therefore, allow tumor specific activation of these toxic drugs by the poorly oxygenated regions of solid tumors. In vivo experiments to test this concept are currently under way.
Materials and methods
Cell culture and hypoxic treatment HT1080 cells were obtained from the American Type Culture Collection, Rockville, MD, USA and cultured in alpha-MEM with 10% FCS in a well-humidified incubator with 5% CO 2 at 37°C. For transient transfection experiments, 5 × 10 5 exponentially growing cells were plated on a six-well culture dish overnight as described previously. 7 Hypoxic conditions were achieved using prewarmed aluminum hypoxic chambers 35 by evacuation and gassing with 95% N 2 /5% CO 2 , and then the tightly sealed chambers were incubated at 37°C for 6-18 h. The oxygen concentrations were controlled to be the desired levels from 2% to 0.02% as described previously. 35 Plasmid construction, transfection and reporter assay The methods for construction of a 5HRE/VEGF/E1b vector and preparation of the multimers of HREs were previously described. 7 Schematic diagrams for each construct are shown in each Figure. To search for an optimal construction of a vector having large hypoxia inducibility, we generated a series of luciferase reporter Gene Therapy plasmids by combinations of the following gene fragments into the pGL3 vector (Promega, Madison, WI, USA): the 385 bp fragment of the VEGF gene derived from the 5′ flanking region at position −1175 to −790 from the transcription start site 36 and the multiple copies of a HIF-1 consensus sequence of the human VEGF gene. 7, 37 To make a 5HRE/EF-1a vector, an EcoRI-XhoI fragment from a pEF/myc/cyto vector (Invitrogen, Carlsbad, CA, USA) was cloned into a pcDNA3 vector (Invitrogen) and a human EF-1a promoter prepared as a BamHI-NcoI fragment was inserted into a BglII-NcoI site of the 5HRE/pGL3 vector. A synthetic fragment consisted of a human cytomegalovirus minimal promoter (hCMVmp) and linker sequences was also inserted at a BglII-HindIII site of 5HRE/pGL3 for making a 5HRE/hCMVmp vector. The hCMVmp using in this study encompasses the sequence between −53 and +7 of the original promoter sequence reported previously. 38 To examine the effects on hypoxia responsiveness via a putative mRNA stability mechanism, we added a fragment from the 3′ UTR of the human VEGF gene behind the luciferase gene. The 1.5 kb of 3′ UTR were obtained by RT-PCR. 26 Total RNA of HT1080 cells after 24 h hypoxic treatment were extracted by RNeasy kit (Qiagen, Santa Clarita, CA, USA) and the first-strand templates were prepared by Superscript reverse transcription system (Gibco BRL, Rockville, MD, USA). PCR was performed using Elongase enzyme mixture (Gibco BRL) with the following paired primers: 5′-CGCTCTAGATAGACA-CACCCACCCACATA-3′ and 5′-GAGAGCTAGCCT ACGGAATATCTCGAAAAACTGCAC-3′. The PCR conditions were 94°C, 1 min; 52°C, 1 min; 68°C, 2 min; for 35 cycles. The fragment were inserted at XbaI site of pGL3 and 5HRE/VEGF/E1b vectors.
For transient transfection assays, these test plasmids and the control pRL-CMV plasmid were co-transfected into tumor cells with the Superfect reagent (Qiagen) followed by incubation for 3 h. The culture dishes were washed with PBS twice and fresh growth media added. At 36 h after transfection, the cells were trypsinized and plated into the notched glass dishes overnight before the hypoxic treatment. After 2 h of reoxygenation, cell lysates were prepared with 400 l of passive lysis buffer using a Dual Luciferase Assay kit (Promega) and the luciferase activities were measured by a luminometer. To minimize the variations of transfection efficiency between experiments, we performed dual luciferase measurements and normalized the luciferase activities of test plasmids with those of the control plasmids as described previously. 7 In experiments comparing the actual amount of gene expression among various promoters, protein concentrations of the cell lysates were also determined by Bradford's method (BioRad, Hercules, CA, USA).
